Mizuho Securities analyst Ann Hynes has reiterated their bullish stance on DGX stock, giving a Buy rating yesterday.
Ann Hynes has given her Buy rating due to a combination of factors that highlight Quest Diagnostics as a resilient investment in a challenging economic landscape. The company has reaffirmed its 2025 guidance and long-term growth outlook, which is particularly reassuring amidst potential regulatory challenges and broader economic uncertainties. Quest Diagnostics demonstrates strong earnings visibility, robust cash flow generation, and maintains a solid balance sheet, all of which contribute to its attractiveness as an investment.
Quest Diagnostics has outlined several strategic growth initiatives that bolster its market position and potential for expansion. These include partnerships with health plans and systems, advancements in diagnostics, and enhancements in data analytics. Additionally, the company’s commitment to cost-saving measures through its Invigorate Program and investments in Project Nova are expected to drive profitability and operational efficiency. The company’s strategic focus on mergers and acquisitions, particularly in hospital outreach labs, further supports its growth trajectory and underpins the positive outlook reflected in the Buy rating.
According to TipRanks, Hynes is a 5-star analyst with an average return of 9.3% and a 61.09% success rate. Hynes covers the Healthcare sector, focusing on stocks such as Quest Diagnostics, CVS Health, and UnitedHealth.
In another report released yesterday, Morgan Stanley also reiterated a Buy rating on the stock with a $172.00 price target.